Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Hu Zhou, Xuewen Song, Zengmei Sheng, Feng Zhang, Guocai Wu, Lidong Zhao, ZePing Zhou, Lihong Shou, Lili Chen, Xiaotao Wang, Jian Huang, Rong Fu, Dan Chen, Ruibin Huang, Zongjiu Jiao, Jian Lu, Yajun Ruan, Yu Jiao

Blood (2024) 144 (Supplement 1): 5406.

https://doi.org/10.1182/blood-2024-200074

Published: 2024

Journal Articles

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Luqun Wang, Wei Yang, Ting Niu, Yafei Wang, Rong Fu, Yuping Zhong, Kaiyang Ding, Kai Sun, Baijun Fang, Hong Liu, Wenbin Qian, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu

Blood (2024) 144 (Supplement 1): 7874.

https://doi.org/10.1182/blood-2024-201134

Published: 2024

Journal Articles

Analysis of Clinical Characteristics and Pathogenic Mechanisms of Non-Severe Aplastic Anemia Associated with Active Sternum Bone Marrow Hyperplasia

Congwei Zhong, Yiyu Guo, Yinxing Wang, Chunyan Liu, Rong Fu

Blood (2024) 144 (Supplement 1): 5694.

https://doi.org/10.1182/blood-2024-210288

Published: 2024

Journal Articles

Influence of Intestinal Flora Metabolism on Aplastic Anemia and Its Mechanism

Xiaorui Meng, Rong Fu

Blood (2024) 144 (Supplement 1): 5693.

https://doi.org/10.1182/blood-2024-209949

Published: 2024

Journal Articles

Efficacy and Safety of Different TPO-RAs Combined with Cyclosporine in the Treatment of NSAA

Ting Wang, Donglan Liu, Nianbin Li, Shuai Gao, Lijuan Li, Jia Song, Huaquan Wang, Rong Fu

Blood (2024) 144 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2024-209539

Published: 2024

Journal Articles

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

Fu Cheng Cheng, Song Jin, Junling Zhuang, Xin Zhou, Fan Zhou, Yuhua Li, Kaiyang Ding, Ting Niu, Wenming Chen, Baijun Fang, Li-Li Chen, Rong Fu, Hao Zhang, Jiaping Fu, Xiuju Wang, Sha Liu, Lin Li, Depei Wu

Blood (2024) 144 (Supplement 1): 6970.

https://doi.org/10.1182/blood-2024-204366

Published: 2024

Journal Articles

CAR-Tscm Cells As an Effective Immune Treatment to Multiple Myeloma Patients

Liu Zhaoyun, Sr., Rong Fu

Blood (2024) 144 (Supplement 1): 6852.

https://doi.org/10.1182/blood-2024-208878

Published: 2024

Journal Articles

Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH

Junshu Wu, Hui Liu, Liyan Li, Wei Wang, Zhaoyun Liu, Rong Fu

Blood (2024) 144 (Supplement 1): 1078.

https://doi.org/10.1182/blood-2024-208178

Published: 2024

Journal Articles

Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT ± MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Label, Multicenter Clinical Trial

Rong Fu, Jia Song, Hui Liu, Zongjiu Jiao, Da Gao, Kai Ding, Jie Zhuo, Huijuan Jiang, Shan Gao, Yue Ren, Lijuan Li, Yihao Wang

Blood (2024) 144 (Supplement 1): 7786.

https://doi.org/10.1182/blood-2024-209056

Published: 2024

Journal Articles

Analysis of Anxiety and Depression Status and Influencing Factors in Multiple Myeloma Patients

Mengran Gao, Wei Zhang, Rong Fu

Blood (2024) 144 (Supplement 1): 7880.

https://doi.org/10.1182/blood-2024-210353

Published: 2024

Journal Articles

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

Rong Fu, Hong Yu, Aijun Liu, Rui Hou, Zunmin Zhu, Junling Zhuang, Li Bao, Zhenling Li, Lihong Liu, Luoming Hua, Yanping Ma, Da Gao, ARong Jin, Xiaohui Suo, Wei Yang, Yuansong Bai, Deqiang Zheng, Wenming Chen

Blood (2024) 144 (Supplement 1): 7846.

https://doi.org/10.1182/blood-2024-209471

Published: 2024

Journal Articles

The Efficacy and Safety of Daratumumab-Based Regimens in the Initial Treatment of Amyloid Light-Chain Amyloidosis

Kai Ding, Rong Fu

Blood (2024) 144 (Supplement 1): 6891.

https://doi.org/10.1182/blood-2024-209723

Published: 2024

Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Miao Chen, Hong Yu, Aijun Liu, Wei Wang, Xiaoqi Qin, Ziping Li, Yanping Ma, Wenming Chen, Rong Fu, Junling Zhuang

Blood (2024) 144 (Supplement 1): 7038.

https://doi.org/10.1182/blood-2024-210284

Published: 2024

Journal Articles

Role of IRF-1 in Regulating the Proliferation and Function of Bone Marrow NK Cells in Patients with Severe Aplastic Anemia

Tian Zhang, Zixuan Liu, Chunyan Liu, Nan Song, Rong Fu

Blood (2024) 144 (Supplement 1): 4083.

https://doi.org/10.1182/blood-2024-209531

Published: 2024

Journal Articles

Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia

Mengran Gao, Ling Deng, Xinrui Zhang, Chunyan Liu, Rong Fu

Blood (2024) 144 (Supplement 1): 1319.

https://doi.org/10.1182/blood-2024-209907

Published: 2024

Journal Articles

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2024-204620

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)

Hu Zhou, Bingjie Ding, Tiejun Gong, Xiangzhou Du, Xiaoming Li, Yinghui Lai, Zhenyu Yan, Rong Fu, Xin Du, Qian Zhao

Blood (2024) 144 (Supplement 1): 711.

https://doi.org/10.1182/blood-2024-198573

Published: 2024

Journal Articles

T-Lymphocyte Suppression By ULK2 High Expression of CD14 + Monocytes in Patients with Multiple Myeloma

Fengping Peng, Zhaoyun Liu, Fengjuan Jiang, Rong Fu

Blood (2024) 144 (Supplement 1): 1897.

https://doi.org/10.1182/blood-2024-209222

Published: 2024

Journal Articles

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood (2023) 142 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2023-188961

Published: 2023

NARROW

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

Real-World Clinical Outcomes of Daratumumab-Based Regimens in Chinese Patients with Multiple Myeloma By Cytogenetic Risk: A Subgroup Analysis of the MMY4032 Study

Analysis of Clinical Characteristics and Pathogenic Mechanisms of Non-Severe Aplastic Anemia Associated with Active Sternum Bone Marrow Hyperplasia

Influence of Intestinal Flora Metabolism on Aplastic Anemia and Its Mechanism

Efficacy and Safety of Different TPO-RAs Combined with Cyclosporine in the Treatment of NSAA

Ixazomib Based Regimens As Front-Line Treatment in Newly Diagnosed Multiple Myeloma Patients in China: A Real-World Data from Infinite Study

CAR-Tscm Cells As an Effective Immune Treatment to Multiple Myeloma Patients

Single-Cell Sequencing Reveals Differential Erythroid Lineage Differentiation in Patients with PNH

Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT ± MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Label, Multicenter Clinical Trial

Analysis of Anxiety and Depression Status and Influencing Factors in Multiple Myeloma Patients

In-Class Transition (iCT) of Proteasome Inhibitor-Based Therapy Prolongs Progression-Free Survival in High-Risk Myeloma Patients: A Real-World Chinese Cohort Study

The Efficacy and Safety of Daratumumab-Based Regimens in the Initial Treatment of Amyloid Light-Chain Amyloidosis

Ixazomib, Pomalidomide and Dexamethasone (IxaPD) Pan-Oral Regimen in the Treatment of Refractory and Relapsed Multiple Myeloma

Role of IRF-1 in Regulating the Proliferation and Function of Bone Marrow NK Cells in Patients with Severe Aplastic Anemia

Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia

Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)

T-Lymphocyte Suppression By ULK2 High Expression of CD14 + Monocytes in Patients with Multiple Myeloma

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only